<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03401125</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-RETRO-ALLO</org_study_id>
    <nct_id>NCT03401125</nct_id>
  </id_info>
  <brief_title>Risk Factors for Allo-immunization in Sickle Cell Disease</brief_title>
  <official_title>Retrospective Study of the Risk Factors for Allo-immunization in Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanane EL KENZ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell patients have a high prevalence of alloimmunization. This high rate of
      alloimmunization can be partially explained by the existence of an antigenic difference
      between the predominantly Caucasian donor population and the sickle cell patients of African
      origin. Genetic and environmental risk factors have also been described.

      The main risk factors that have been shown in retrospective or cross-sectional studies are
      some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte
      concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the
      existence of an inflammatory event at the time of transfusion and the presence of
      anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the
      underlying immunological mechanism is not fully understood.

      The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte
      alloimmunization in pediatric and adult patients with Sickle Cell Disease (with a SS
      genotype) who are being followed at Queen Fabiola University Children's Hospital (HUDERF) and
      at the CHU Brugmann Hospital. The identification of risk factors would allow the
      investigators to improve, or at least adapt, their transfusion policy to certain clinical or
      immuno-haematological situations.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Date of birth</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Date of birth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Sex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood group</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Blood group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extended phenotype</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Sickle cell disease extended phenotype</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibodies</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Presence/absence of irregular anti-erythrocytes antibodies (RAI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of blood transfusions</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Number of blood transfusions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of blood transfusions</measure>
    <time_frame>From birth till the first positive RAI test (up to 50 years)</time_frame>
    <description>Number of blood transfusions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Auto antibodies</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Presence/absence of auto anti-erythrocytes antibodies (RAI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathology</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Medical issue causing the patient to be included in a chronic blood transfusion program</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of the chronic transfusion program</measure>
    <time_frame>january 2013-december 2017</time_frame>
    <description>Duration of the chronic transfusion program</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">401</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Sickle cell disease patients (SS genotype)</arm_group_label>
    <description>Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical file data collection</intervention_name>
    <description>The information described in the 'outcome measures' section will be collected from the medical files of the patients.</description>
    <arm_group_label>Sickle cell disease patients (SS genotype)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Sickle cell disease patients (HbSS genotype) with a history of blood transfusion within the
        CHU Brugmann and the Queen Fabiola University Hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Sickle cell disease patients (HbSS genotype) with a history of blood transfusions within
        the CHU Brugmann and the Queen Fabiola University Hospitals.

        Exclusion Criteria:

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <phone>+ 32 2 477 24 09</phone>
    <email>marie.deleers@chu-brugmann.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanane El Kenz, Ph Biol</last_name>
    <phone>+ 32 2 477 27 34</phone>
    <email>hanane.elkenz@chu-brugmann.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Deleers, Ph Biol</last_name>
      <phone>+ 32 2 477 24 09</phone>
      <email>marie.deleers@chu-brugmann.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Deleers, Ph Biol</last_name>
      <phone>+ 32 2 477 24 09</phone>
      <email>marie.deleers@chu-brugmann.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Hanane EL KENZ</investigator_full_name>
    <investigator_title>Head of Blood Bank</investigator_title>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>Allo-immunization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

